{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose", "query": { "intervention": "High dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6993, "total_pages": 700, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T22:32:29.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06862791", "title": "A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity or Overweight" ], "interventions": [ { "name": "AZD9550", "type": "DRUG" }, { "name": "AZD6234", "type": "DRUG" }, { "name": "Placebo comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 377, "start_date": "2025-02-18", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 29, "location_summary": "Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06862791" }, { "nct_id": "NCT04373317", "title": "Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease Psychosis" ], "interventions": [ { "name": "Pimavanserin", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 358, "start_date": "2022-10-24", "completion_date": "2028-08-24", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 24, "location_summary": "Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04373317" }, { "nct_id": "NCT03424850", "title": "Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Neoplasm" ], "interventions": [ { "name": "HDR brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2018-02-27", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03424850" }, { "nct_id": "NCT01849497", "title": "Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Hypercholesterolemia", "Mixed Dyslipidemia" ], "interventions": [ { "name": "Evolocumab Pre-filled Syringe", "type": "BIOLOGICAL" }, { "name": "Evolocumab AI/pen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 149, "start_date": "2013-04-18", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 21, "location_summary": "Encino, California • Thousand Oaks, California • Ventura, California + 17 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Westlake Village", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849497" }, { "nct_id": "NCT03037385", "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RET-altered Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET-altered Papillary Thyroid Cancer", "RET-altered Colon Cancer", "RET-altered Solid Tumors", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Thyroid Diseases", "Thyroid Neoplasm", "Thyroid Cancer, Papillary", "Carcinoma, Neuroendocrine", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Endocrine System Diseases", "Endocrine Gland Neoplasm", "Head and Neck Neoplasms", "Adenocarcinoma, Papillary", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Neuroendocrine Tumors", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Colonic Neoplasms", "Colorectal Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Disease", "Colonic Diseases", "Intestinal Disease" ], "interventions": [ { "name": "pralsetinib (BLU-667)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-03-17", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037385" }, { "nct_id": "NCT03066115", "title": "Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypoxia", "Hypercapnia" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Intravenous Catheter", "type": "PROCEDURE" }, { "name": "Transcranial Doppler Ultrasound", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 0, "start_date": "2020-12-01", "completion_date": "2021-12-01", "has_results": false, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066115" }, { "nct_id": "NCT03115515", "title": "Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pregnancy Related", "Thyroid" ], "interventions": [ { "name": "levothyroxine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 60, "start_date": "2011-08", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03115515" }, { "nct_id": "NCT03635125", "title": "Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "JNC 7 Stage 1 or 2 Hypertension" ], "interventions": [ { "name": "Nebivolol I", "type": "DRUG" }, { "name": "Nebivolol II", "type": "DRUG" }, { "name": "Baseline Washout Phase", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Trinity Hypertension & Metabolic Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2010-08-30", "completion_date": "2011-07-18", "has_results": false, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 1, "location_summary": "Carrollton, Texas", "locations": [ { "city": "Carrollton", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635125" }, { "nct_id": "NCT06750289", "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Asthma" ], "interventions": [ { "name": "ICS-LABA", "type": "COMBINATION_PRODUCT" }, { "name": "benralizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo for Benralizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 400, "start_date": "2025-03-28", "completion_date": "2028-11-03", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 34, "location_summary": "Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Inglewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750289" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-02T22:32:29.805Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" } ] }